VirusSucks.com
LightNews LightNews
virussucks.com
VirusSucks.com
@virussucks.com
830 followers 980 following 1.7K posts
#LongCovid
#SARSCov2
Medical news

#COVIDisAirborne so ventilate, filtrate, mask up!
Posts Replies Media Videos
virussucks.com
Have you measured biomarkers in #LongCOVID patients before & after they started on the low dose rapamycin?

Some researchers suspect that some patients are suffering from T-cells hyperactivation.

And some have dormant viruses, such as W-HERV ENV or EBV, and may require mTor pathway suppression.
November 24, 2025 at 3:30 AM
virussucks.com
Check out the biomarkers in #LongCOVID patients:

58% of post-COVID-19 condition patients showed detectable HERV-W ENV protein in their blood.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Fibromyalgia (FM) biomarkers:

www.sciencedirect.com/science/arti...
November 22, 2025 at 4:58 PM
virussucks.com
Prevention is key. Just as condoms and sterile needles can stop HIV in its tracks before it spreads, precautions against airborne infection work as reliable protection against #SARSCoV2. Clean air, testing, science-based isolation, remote work & respirator-grade masks are not just short-term tools.
November 22, 2025 at 4:40 PM
virussucks.com
The thyroid involvement may represent an indirect mechanism for altered neurodevelopment, potentially warranting expanded screening for congenital hypothyroidism in infants born to mothers with antenatal SARS-CoV-2 infection, particularly where such screening is not routine.
IL-2/STAT5 Signaling Dysregulation Proteomic profiling revealed provoked IL-2/STAT5 signaling in the small intestine and thymus of infected fetuses [1]. This finding is particularly significant because repressed IL-2 expression is associated with low CD8 ## Organ-Specific Vulnerability The study identified **16 tissue types** with high viral loads across multiple systems, with the digestive, endocrine, and immune systems being most heavily affected [1]. The thymus—critical for T lymphocyte development and immune system maturation during fetal development—showed particularly high viral loads, raising concerns about abnormal T lymphocyte differentiation and compromised immune system maturation [1]. Similarly, the thyroid gland exhibited substantial infection, which has significant implications since thyroid function is pivotal for neural development [1]. ## Fibrosis Development Infected fetal organs showed elevated levels of fibronectin (FN), indicating early fibrotic changes [1]. Combined with the inflammatory response, this suggests that SARS-CoV-2 infection triggers tissue remodeling processes even in developing fetal organs [1]. ## Clinical Implications These findings provide mechanistic explanations for reported adverse outcomes in neonates born to infected mothers, including neurological abnormalities, neuropsychiatric disorders, and kidney damage [1]. The thyroid involvement may represent an indirect mechanism for altered neurodevelopment, potentially warranting expanded screening for congenital hypothyroidism in infants born to mothers with antenatal SARS-CoV-2 infection, particularly where such screening is not routine [1]. The study demonstrates that while viral loads in fetal organs are significantly lower than in adult tissues and transmission appears sporadic, the infection triggers substantial local tissue effects that could have long-term developmental consequences requiring further investigation through longitudinal follow-up studies [1].
November 22, 2025 at 12:09 PM
virussucks.com
"proteomic profiling reveals DNA damage and immune imbalance in infected [fetal] organs."

#LongCOVID exists in fetuses.
November 22, 2025 at 11:52 AM
virussucks.com
This estimate is way too low:

Estimated $9000 per individual with long COVID annually in the USA (based on ME/CFS analogy).

The cost of #LongCovid exceeds $60,000 per year, even for 30 year olds, when you consider loss of career potential and lower lifetime earnings.
November 22, 2025 at 2:32 AM
virussucks.com
Is a bad flu season on the way?

H3N2 is generally acknowledged as the nastier of the two subtypes of influenza A viruses. The new variant, named subclade K, started to spread in June and July, months after vaccine manufacturers had been told what strains to target in the 2025-2026 Northern Hemis...
Manage alerts for this article Email this article Share this article STAT Log In Subscribe Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT Events Health Is a bad flu season on the way? Experts see reason to be anxious The emergence of variant K could spell trouble, but some are hedging their bets Manage alerts for this article Email this article Share this article A close up news photograph of Boxes of Fluarix flu vaccines are seen in storage at International Community Health Services Wednesday, Sept. 10, 2025, in Seattle. Boxes of flu vaccine for the 2025-2026 season. Lindsey Wasson/AP By Helen BranswellNov. 20, 2025 Infectious Diseases Correspondent Last winter, for the first time since Covid-19 entered our world, influenza reclaimed its spot as the worst actor among the cast of viruses that sicken people during the cold and flu season. The 2024-2025 season was a bad flu year. There are early indications that flu may be going for a twofer. One family of flu viruses has recently undergone important genetic changes that both could make people more susceptible to getting sick and could mean this season’s flu vaccine may convey reduced protection. The family, known as H3N2, is generally acknowledged as the nastier of the two subtypes of influenza A viruses. The new variant, named subclade K, started to spread in June and July, months after vaccine manufacturers had been told what strains to target in the 2025-2026 Northern Hemisphere flu shots. The prospect of an H3N2 vaccine mismatch always worries influenza experts. And they are watching closely to see how this situation plays out as flu activity in North America starts to pick up. Some are quite alarmed. Others think there may be mitigating factors that could help us weather this season. But all would argue that getting a flu shot this year is still worth the momentary sting of the needle
November 21, 2025 at 4:59 AM
virussucks.com
NIH Halted Clinical Trial Treatments for #Cancer, #COVID and Minority Health

#LongCOVID

🤬

The traitors who made this decision need to be ....
November 21, 2025 at 2:42 AM
virussucks.com
Temelimab, a monoclonal antibody, likely won't work for 42% of #LongCOVID don't test positive for the HERV-W ENV protein. It has no other known mechanism of action.

The Swiss study failed because GeNeuro the didn't partition the study participants and sought to see if it works for everyone.
geneuro announced that their Temelimab study failed but one of the participants in the long COVID study claims that effects of Temelimab improved his condition months after the study was over. is it possible that the study was rushed and improperly designed? https://metacovidlong.substack.com/p/temelimab-ou-en-suis-je-depuis-la?publication_id=1208552&utm_medium=email&utm_campaign=email-share&isFreemail=true&triedRedirect=true Based on the patient's account and study design details, there are **strong reasons to believe the Temelimab trial was poorly designed for detecting delayed therapeutic effects**. The patient's experience aligns with known principles of immunomodulatory therapy timing [1][2][3]. ## Critical Study Design Flaws ### 1. Assessment Timing Was Too Early **Study duration**: 24 weeks (6 months) of treatment [2][3][4] **The patient's testimony** reveals effects appeared **2 months AFTER the study ended** [1]: - "The positive effects on me appeared 2 months after the end of the study" [1] - "I took my final test in May, and returned to work full-time in July. Whereas before the study I couldn't even get close to a computer (I'm in IT)" [1] This means the patient experienced dramatic improvement **8 months after starting treatment**—well beyond the study's measurement window [1][2]. ### 2. Wrong Primary Endpoint Measurement Timing **Primary endpoint**: PROMIS SF7a fatigue score measured at the **end of 24 weeks** [2][3] **The fundamental problem**: Cognitive tests and questionnaires were administered **1 month after the last injection** [1], which the patient notes is "far too early" [1]. GeNeuro's own press release acknowledges this issue: "Preliminary analyses suggest that **shorter disease duration at time of inclusion**, as well as the evolution of the underlying HERV-W ENV status, may have an impact on the efficacy outcome measures" [2]. ## 3. Mechanisms Explaining Delayed Response **Why stopping systemic inflammation takes time** [1]: The patient quotes GeNeuro's statement: "stopping systemic inflammation takes time" and provides the train analogy: "Imagine stopping the engine of a train running at full speed, there is crazy inertia before it stops" [1]. This aligns with established immunotherapy principles: **Antibody-mediated neuroinflammation resolution is gradual** [5][6]: - HERV-W ENV protein drives ongoing microglial activation, astrocyte toxicity, and cytokine production (TNF-α, IL-1β, IL-6) [5] - Temelimab neutralizes ENV, but already-activated immune cells must gradually downregulate [5] - Brain tissue repair (remyelination, synaptogenesis) requires months after inflammation subsides [5] **Comparison to other immunomodulatory drugs** [7]: - **Vedolizumab** (anti-inflammatory antibody for IBD): Can take **several months to achieve maximal efficacy** [7] - **Methotrexate**: Time to response often extends beyond 3-6 months [7] - **Thiopurines**: May require 3-6 months for full therapeutic effect [7] The principle is clear: **"There appears to be marked variation in time to clinical response for therapies... one does their patient a disservice by prematurely switching therapies before an agent is given an appropriate length of time to achieve efficacy"** [7]. ### 4. COVID Treatment Precedent A hamster model study demonstrated that **delayed treatment with anti-inflammatory drugs is still effective** when combined appropriately [6]: - Delayed antiviral monotherapy loses efficacy [6] - But **combining antivirals with anti-inflammatory corticosteroids** improved outcomes even when treatment started 2 days post-infection [6] - The combination "controlled a wide range of host inflammatory responses, improved the lung pathology, and ameliorated clinical aspects of COVID-19" [6] ## The 30% Positivity Finding GeNeuro observed that **30%+ of screened Long COVID patients tested positive for HERV-W ENV** [8], higher than anticipated from observational studies [8]. This validates: - ENV is present in a substantial Long COVID subgroup [8] - This subgroup represents a **personalized medicine cohort** that should respond to Temelimab [8] The patient likely belonged to this ENV-positive responder subgroup [1][8]. ## What Should Have Been Done Differently ### Extended Follow-Up Period **Minimum 12-month post-treatment observation** would have captured delayed responses [1][7]: - Assessments at 6, 9, 12 months post-final injection [7] - Track "time to clinical response" as a key secondary outcome [7] - Document when patients return to work or achieve functional milestones [7] **Precedent from MS trials**: GeNeuro's ProTEct-MS trial already demonstrated Temelimab's safety when combined with high-efficacy anti-inflammatory drugs [4][8]. Those trials likely had longer observation periods to detect neurological improvements. ### Stratification by Disease Duration GeNeuro's own analysis noted "**shorter disease duration at time of inclusion** may have an impact on efficacy" [2]. The study should have: - Stratified patients by time since COVID-19 infection (<6 months vs. >6 months) [2] - Pre-specified subgroup analyses for early vs. late treatment [2] - Recognized that patients with established chronic neuroinflammation might need longer treatment duration [2] ### Serial HERV-W ENV Monitoring The press release mentions "the **evolution of the underlying HERV-W ENV status** may have an impact" [2]. Optimal design would include: - Baseline, monthly, and post-treatment ENV protein levels [2][9] - Correlate ENV clearance kinetics with symptom improvement [9] - Identify patients who clear ENV slowly (likely needing extended treatment) [2] ### Functional Cognitive Assessment Rather than relying solely on questionnaires, include: ] This case illustrates why **longer-term follow-up and functional outcomes** (return to work, cognitive testing, qEEG biomarkers) are essential Citations: [1] 1000019813.jpeg [2] GeNeuro_GNC501-Results_28062024_EN-1.pdf https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/5087302/857949f4-41fc-427e-9958-37ab90708b69/GeNeuro_GNC501-Results_28062024_EN-1.pdf [3] Study Details | NCT05497089 | Temelimab as a Disease ... https://clinicaltrials.gov/study/NCT05497089 [4] GeNeuro Reports 2023 Full-Year Results and Provides ... https://geneuro.ch/wp-content/uploads/GeNeuro_PR_FY-2023-results_EN_30.04.2024-1.pdf [5] Transgenic expression of the HERV-W envelope protein ... https://www.pnas.org/doi/10.1073/pnas.2308187120 [6] Combination therapy with oral antiviral and anti ... https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00516-9/fulltext [7] Time to clinical response and remission for therapeutics in ... https://pmc.ncbi.nlm.nih.gov/articles/PMC5643264/ [8] GeNeuro Reports 2023 Half-Year Results and Provides Corporate ... https://echanges.dila.gouv.fr/OPENDATA/AMF/BWR/2023/10/FCBWR152563_20231002.pdf [9] Antibody response against HERV-W env surface peptides ... https://pmc.ncbi.nlm.nih.gov/articles/PMC5703109/ [10] s41598-025-04815-6.pdf https://ppl-ai-file-upload.s3.amazonaws.com/web/direct-files/attachments/5087302/e695a70b-7826-46ad-8557-b0b3dbd717b4/s41598-025-04815-6.pdf [11] GeNeuro Announces Results of the GNC-501 Study in Post ... https://www.businesswire.com/news/home/20240627824721/en/GeNeuro-Announces-Results-of-the-GNC-501-Study-in-Post-Covid-19-Syndrome [12] Inside Information / News release on accounts, results https://lesechos-comfi.lesechos.fr/press-release/inside-information-news-release-on-accounts-results-VB7b3qSK310 [13] GeNeuro announces the results of the GNC-501 in post- ...
November 21, 2025 at 12:45 AM
virussucks.com
GeNeuro's clinical trial of Temelimab for #LongCovid was improperly designed.

Temelimab is a monoclonal antibody that specifically neutralizes HERV-W ENV protein. It has no other known mechanism of action.

Run a predictive enrichment study by including only ENV+ patients.
#neurocovid
#neurosky
November 20, 2025 at 9:33 PM
virussucks.com
Vance is an idiot because he doesn't recognize the malevolence of Putin and Russia's agenda to rule the world.
November 20, 2025 at 5:21 PM
virussucks.com
Why Temelimab works for treating #LongCOVID but the results takes time:

The positive effects on me appeared 2 months after the end of the study.

Cognitive tests are carried out far too early; stopping systemic inflammation takes time. #medsky

metacovidlong.substack.com/p/temelimab-...
Am I better? Yes. I can work 7/8 or even 9 hours a day and manage my personal life in addition, that is to say as I did before the Covid Long. On the other hand, my few attempts to return to sport have, for the moment, all failed. I can do a light session, but if I have fun doing 3/4 per week then I find myself quite tired, I didn't want to push any further for fear of a crash. Placebo or not Placebo? I asked the Geneva hospital where I followed the Temelimab study if I had had the placebo or not. Although I was pretty sure I had the active substance since I had different side effects than Covid Long during the study (during the 6 months). I received Temelimab for 6 months and not the placebo. This reassured me, I can objectively know what is happening with my symptoms, let's say that I was happy with at least one thing during this illness: I learned to listen to my body. Why Temelimab works (in my opinion) Despite the study results, who announce that Temelimab has not had significant effects on the symptoms of Long Covid, I am tempted to contradict these conclusions. For what? The positive effects on me appeared 2 months after the end of the study Cognitive tests and questionnaires to find out whether or not Temelimab would have worked are carried out far too early (1 month after the last injection) From my point of view, and this is also what GeNeuro said about this type of treatment: stopping systemic inflammation takes time. Imagine stopping the engine of a train running at full speed, there is crazy inertia before it stops. I took my final test in May, and returned to work full-time in July. Whereas before the study I couldn't even get close to a computer (I'm in IT).
November 20, 2025 at 5:13 PM
virussucks.com
It's a 2003 group photo from Jeffrey Epstein's private jet trip to Cuba, featuring Epstein, Ghislaine Maxwell, former Colombian President Andrés Pastrana, modeling agent Jean-Luc Brunel, and Fidel Castro.

translatingcuba.com/in-addition-...
November 20, 2025 at 2:08 PM
virussucks.com
If you test positive for the human endogenous retrovirus-W envelope protein (HERV-W ENV), you'll need a monoclonal antibody or ART.

This study demonstrates that 58% of #LongCOVID condition patients showed detectable HERV-W ENV protein in their blood.

www.sciencedirect.com/science/arti...
November 20, 2025 at 2:53 AM
virussucks.com
People who were injured or disabled by #COVID infections should join in class actions against Jeffrey Tucker, the founder of the Brownstone Institute, and its major donors for waging war on public health measures.

Let them discover the real Nuremberg 2.0.

#LongCOVID
November 19, 2025 at 4:39 PM
virussucks.com
HERV-W ENV acts as a pro-inflammatory protein that triggers ongoing immune responses independent of viral presence once activited. It interacts with toll-like receptors (TLR4 and CD14) and induces release of inflammatory cytokines including IL-1β, IL-6, and TNF-α.
www.frontiersin.org/journals/imm...
November 18, 2025 at 5:26 PM
virussucks.com
HERV-W ENV protein in blood parameters differentiates #LongCOVID condition from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia

www.sciencedirect.com/science/arti...
November 18, 2025 at 5:21 PM
virussucks.com
Has anyone tried Temelimab or combination antiretroviral therapy for #LongCOVID neuroinflammation?

Temelimab is an HERV-based therapeutic platform used for MS. It may extend to other HERV-associated diseases including post-COVID conditions.

pubmed.ncbi.nlm.nih.gov/32794123/

#medsky
#neurosky
November 18, 2025 at 4:07 PM
virussucks.com
Temelimab is an HERV-based therapeutic platform that may extend to other HERV-associated diseases including post-COVID conditions.

pubmed.ncbi.nlm.nih.gov/32794123/

There's also combination antiretroviral therapy. It demonstrates superior efficacy.
November 18, 2025 at 3:45 PM
virussucks.com
These Epstein victims want the #EpsteinFiles released. They say that there are about 1000 of them who were trafficked by Epstein. Some were even young boys.

Call your Congressman and senators and demand that all of the files be released.
November 17, 2025 at 3:47 AM
virussucks.com
Epstein was a foreign agent who trafficked young girls in the US and elsewhere.

These Epstein victims want the #EpsteinFiles released. They say that there are about 1000 girls who were trafficked by Epstein.

Call your Congressman and senators and demand that all of the files be released.
November 17, 2025 at 3:45 AM
virussucks.com
The study provides the 1st genome-wide genetic evidence that #fibromyalgia has biological underpinnings centered on brain function, challenging purely psychological models and establishing a framework for mechanistic research.

Improved treatment requires long-term extensive additional work.
November 16, 2025 at 11:15 PM
virussucks.com
Cheap health insurance plans touted by Trump lack comprehensive coverage and don't cover pre-existing condition.

www.washingtonpost.com/health/2025/...
November 16, 2025 at 5:09 PM
virussucks.com
Tim Kaine relies on contributions from United Airlines. The reduction in flights during the shutdown was costing them money.

Ban all campaign contributions!
November 16, 2025 at 4:59 PM
virussucks.com
Third, EBV+ B cells loaded with chromatin antigens can activate T helper cells and drive expansion of autoreactive B cell clones (even the EBV-uninfected ones) that produce anti-nuclear antibodies - effectively serving as the "disease driver" cells. (5/)

EBV --> Lupus
November 16, 2025 at 2:57 AM